The United States Food and Drug Administration has granted tentative approval to the world's first generic version of lenacapavir, a highly effective HIV-prevention medicine administered twice a year, marking a significant advance in efforts to make long-acting protection affordable in developing countries.
Indian pharmaceutical manufacturer Dr. Reddy's Laboratories secured the regulatory clearance on Monday, November 2, following an accelerated development programme supported by Unitaid, the Clinton Health Access Initiative and South Africa's Wits Reproductive Health and HIV Institute.
Under an existing international agreement, the generic injection is expected to cost approximately $40 per person annually in 120 low- and middle-income countries covered by voluntary licensing arrangements with Gilead Sciences, the developer of the original medicine.
The first supplies could reach selected countries before the end of 2026, with broader distribution anticipated in 2027.
The approval represents a major step towards expanding access to a medicine that has demonstrated exceptionally high levels of protection against HIV infection in clinical trials.
However, the FDA's decision does not mean the generic is immediately available worldwide. National approvals, procurement funding and distribution arrangements remain necessary.
What the FDA approved
Dr. Reddy's received what the FDA calls tentative approval for its generic lenacapavir injection.
This designation means the product has satisfied the agency's relevant standards for quality, safety and efficacy, but cannot yet be marketed in the United States because of patent or exclusivity restrictions protecting the original medicine.
The distinction is important.
The regulatory decision can support procurement and accelerate approvals in other countries, but it is not a universal marketing authorisation.
Lenacapavir was originally developed by Gilead Sciences and approved in the United States for HIV prevention in June 2025 under the brand name Yeztugo.
Dr. Reddy's is the first of six manufacturers licensed by Gilead to receive tentative FDA approval for a generic version.
The approval was secured approximately 16 months after the original product's authorisation, a considerably shorter interval than the delays historically associated with affordable generic versions of major medical innovations.
Why lenacapavir is significant
Lenacapavir is a long-acting antiretroviral medicine used for pre-exposure prophylaxis, commonly known as PrEP.
PrEP is medication taken by people who do not have HIV but face a risk of acquiring the virus.
Traditional oral PrEP requires regular dosing, commonly once daily.
Lenacapavir provides a different option, with injections administered at approximately six-month intervals.
That schedule may help people who struggle to take daily medication consistently or face difficulties accessing healthcare services frequently.
Clinical trials involving people at substantial risk of HIV demonstrated extremely high protection against new infections.
However, the medicine is not a vaccine, and its effectiveness should not be described as an absolute guarantee that infection cannot occur.
People receiving lenacapavir for prevention require appropriate HIV testing before starting and during continued use.
It is not a cure for HIV.
A major reduction in cost
The proposed generic price represents one of the most important aspects of the announcement.
Under the partnership agreement, Dr. Reddy's will supply generic lenacapavir at approximately $40 per person per year to eligible countries.
That compares with the original product's US list price of approximately $28,218 annually before insurance or other discounts.
The two prices apply to different markets and purchasing arrangements, so the comparison does not mean every patient currently pays the full American list price.
Nevertheless, the difference illustrates the scale of the affordability challenge facing global health programmes.
The $40 agreement could make twice-yearly HIV prevention more accessible to public health systems operating under tight budgets.
The final cost of delivering the medicine to patients will also depend on procurement, transportation, clinical services, testing and national financing arrangements.
Africa stands to benefit
Sub-Saharan Africa remains central to global HIV prevention efforts.
According to the Clinton Health Access Initiative, more than 125,000 people across 10 early-adopter African countries have already started receiving Gilead's original lenacapavir product.
The introduction of an affordable generic could allow participating countries to expand beyond those initial programmes.
Women and young people facing elevated HIV risks may particularly benefit from having additional prevention options.
Long-acting medication can also address practical barriers associated with daily tablets, including adherence difficulties and concerns about privacy.
But affordability alone will not guarantee widespread access.
Health systems must train workers, secure reliable supplies, provide testing and ensure that people can obtain the medicine without discrimination.
What the approval means for Nigeria
Nigeria has already begun introducing lenacapavir into its HIV prevention programme.
In March 2026, the Federal Ministry of Health and Social Welfare announced the introduction of the long-acting medicine with support from the World Health Organization, the Global Fund, PEPFAR and other partners.
The WHO reported that Nigeria had approximately 1.9 million people living with HIV.
Initial implementation plans covered Benue, Akwa Ibom, Anambra, Ebonyi, Gombe, Kwara, the Federal Capital Territory and Cross River.
Nigeria is expected to receive approximately 180,000 doses by 2028 under its existing rollout plans.
Monday's generic approval is a separate development from the earlier Nigerian launch.
It creates a potential route towards more affordable supplies, but does not establish that Dr. Reddy's generic has already been purchased, registered or distributed in Nigeria.
Any Nigerian deployment will depend on national regulatory and procurement decisions.
Regional Office for Africa
International partnership accelerates development
The generic was developed through a collaboration involving Dr. Reddy's, Unitaid, the Clinton Health Access Initiative and Wits RHI.
The partnership combined technical expertise, financing, regulatory support and an early pricing commitment.
Gilead had previously granted voluntary licences to six manufacturers, allowing them to produce versions of lenacapavir for specified markets.
Dr. Reddy's used an accelerated regulatory approach that brought the generic through FDA review substantially faster than many previous HIV medicines.
The partners say this model could provide a framework for making future medical breakthroughs available more quickly in countries with limited resources.
Approval does not guarantee immediate access
Despite the regulatory milestone, significant challenges remain.
Countries must determine how the generic will fit into existing HIV prevention programmes.
Some will need separate national approvals, while others may use regulatory reliance arrangements to accelerate their decisions.
Procurement agencies must also secure sufficient financing.
Health facilities will require training, testing capacity and systems for monitoring patients.
The medicine can cause side effects, including injection-site reactions, headache and nausea.
HIV testing is particularly important because the use of lenacapavir by someone with an undiagnosed infection can create a risk of drug resistance.
These clinical considerations reinforce the need for supervised medical delivery rather than unsupervised use.
What happens next
Dr. Reddy's and its partners expect initial generic supplies to reach some eligible countries before the end of 2026.
Zambia has been identified as a possible early recipient.
Broader availability is expected during 2027, subject to regulatory approvals, financing and distribution readiness.
For Nigeria and other African countries, the next phase will involve determining how affordable generic supplies can support national prevention strategies.
The development is significant because it brings an innovative HIV-prevention medicine closer to a price that public health programmes may be able to sustain.
Its long-term impact will depend on whether governments, manufacturers and international partners can turn regulatory progress into reliable access for the people who need protection.
The FDA's tentative approval is therefore an important milestone, but not the end of the process.
The next challenge is ensuring that a medicine capable of preventing new HIV infections reaches communities across Africa and other eligible regions at the promised affordable price.
